{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-097013","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2023-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.956097+00:00","generated_at":"2026-06-07T10:44:22.318102+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pasithea shareholders approve 2023 equity plan and reverse split authorization","bullets":["Stockholders approved Pasithea 2023 Stock Incentive Plan: 2.5M shares reserved plus rollover of unused 2021 plan shares.","Reverse stock split authorized (1:2 to 1:20) at Board discretion within one year; corresponding reduction in authorized shares allowed.","All five director nominees elected: Dr. Tiago Reis Marques, Prof. Lawrence Steinman, Simon Dumesnil, Dr. Emer Leahy, Alfred Novak.","Marcum LLP ratified as independent auditor for FY 2023; annual meeting partially adjourned to Dec. 28 for additional governance proposals.","Proxies remain open only for adjourned proposals (charter amendment, classified board, written consent restrictions)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-097013","json":"https://secwatch.observer/filing/0001213900-23-097013.json","markdown":"https://secwatch.observer/filing/0001213900-23-097013.md","text":"https://secwatch.observer/filing/0001213900-23-097013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/0001213900-23-097013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/ea190360-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:44:22.318102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e527036f95f87be746e2f228667e22974c3c277","claim":"Pasithea Therapeutics Corp. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a specific ratio ranging from one-for-two to one-for-twenty at the 2023-12-19 meeting.","evidence_excerpt":"FOR AGAINST ABSTAIN BROKER NON-VOTES 13,432,469 1,181,664 156,671 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/0001213900-23-097013-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-19"}],"fact_type":"shareholder_vote"},{"claim_id":"7776f94382ee96d5e49b7f1bbf67f29a0b113fe1","claim":"Pasithea Therapeutics Corp. shareholders approved Approval of the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan at the 2023-12-19 meeting.","evidence_excerpt":"FOR AGAINST ABSTAIN BROKER NON-VOTES 9,196,502 1,520,422 987,467 3,066,413","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/0001213900-23-097013-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-19"}],"fact_type":"shareholder_vote"},{"claim_id":"7af338674cab632e02e803b051cbcbb6b4b0e413","claim":"Pasithea Therapeutics Corp. shareholders approved Election of each of Dr. Tiago Reis Marques, Prof. Lawrence Steinman, Simon Dumesnil, Dr. Emer Leahy and Alfred Novak at the 2023-12-19 meeting.","evidence_excerpt":"The appointment of each of the foregoing directors was approved by a plurality of the votes cast at the Annual Meeting as follows: FOR WITHHELD BROKER NON-VOTES Dr. Tiago Reis Marques 11,433,844 270,547 3,066,413 Prof. Lawrence Steinman 11,434,292 270,099 3,066,413 Simon Dumesnil 11,409,027 295,364 3,066,413 Dr. Emer Leahy 11,408,775 295,616 3,066,413 Alfred Novak 11,369,003 335,388 3,066,413","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/0001213900-23-097013-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-19"}],"fact_type":"shareholder_vote"},{"claim_id":"90f087dd8cffa9f2a535bc81172ea3e38afba19d","claim":"Pasithea Therapeutics Corp. shareholders approved Ratification of appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-19 meeting.","evidence_excerpt":"FOR AGAINST ABSTAIN BROKER NON-VOTES 13,742,119 992,581 36,104 N/A","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023097013/0001213900-23-097013-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-19"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}